SCHEMBL1463809

SCHEMBL1463809

CC(C)CCC1(C(=O)O)CC(=O)O1

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.35
ALOX12 P18054 1/20 0.34
AKT1 P31749 3/20 0.33
POLB P06746 1/20 0.33
CDC25A P30304 1/20 0.32
SORT1 Q99523 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12745666 1.00 PRKCA (0.35) PRKCAALOX12AKT1POLBCDC25A
SCHEMBL12745665 0.86 PRKCA (0.35) PRKCAALOX12AKT1CDC25ASORT1
SCHEMBL12826430 0.83 PRKCA (0.33) PRKCAALOX12AKT1SORT1
SCHEMBL1463688 0.79 SIRT2 (0.32) POLB
SCHEMBL12746067 0.77 PRKCA (0.37) PRKCAAKT1
SCHEMBL12745986 0.75 DDB1 (0.41)
SCHEMBL1463776 0.68
SCHEMBL12746030 0.65
SCHEMBL20150669 0.65
SCHEMBL18584058 0.65 BLM (0.38) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006231-B2 Cephalotaxus esters, methods of synthesis, and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2015-04-14 US disclosed
US-20140343039-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2014-11-20 US disclosed
US-20140343039-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2014-11-20 US disclosed
US-20140171416-A1 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2014-06-19 US disclosed
US-8466142-B2 Cephalotaxus esters, methods of synthesis, and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-06-18 US disclosed
US-8466142-B2 Cephalotaxus esters, methods of synthesis, and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-06-18 US disclosed
US-20120022250-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2012-01-26 US disclosed
US-20120022250-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2012-01-26 US disclosed
US-20110071097-A1 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-03-24 US disclosed
US-20110071097-A1 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-03-24 US disclosed
EP-2260041-A2 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF Sloan Kettering Institute For Cancer Research (US) 2010-12-15 EP disclosed
WO-2009148654-A2 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071097-A1 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF COASY, CXCR4, CETP PRKCA 2723/4885ALOX12 13/4885AKT1 1629/4885
US-20120022250-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS CHRM1, OPRM1, CHRM2 PRKCA 4497/4885ALOX12 575/4885AKT1 2040/4885
US-20140343039-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS CFH, C5, CHRM1 PRKCA 3547/4885ALOX12 299/4885AKT1 3281/4885
US-20140171416-A1 CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF COASY, CXCR4, CETP PRKCA 2723/4885ALOX12 13/4885AKT1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.